The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Suzetrigine and the Promise of Non-Opioid Pain Relief. At the forefront of Vertex's expansion into pain management is suzetrigine (VX-548), a novel drug candidate with the potential to ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex Pharmaceuticals’ Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain. The twice-daily pill is the first in a new class of medicines that block a ...

Acute pain is something more than 80 million Americans fill prescriptions to treat each year, according to Vertex. As opposed to chronic pain, which can last well after an injury or illness has ...

If Vertex does get payer buy-in, Journavx could be an exception to a longstanding, unwritten rule in pain management: fresh therapies take a while to reach patients.

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, ... A Promising Non-Opioid Solution to Acute Pain Management. TipRanks. Oct. 21, 2024, 04:55 AM.

Vertex's stock has risen 18% since last December, ... to believe VK-548's potential in neuropathies is more interesting than its potential in a crowded and complex acute pain management market.

Leerink Partners analyst David Risinger maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $600.00. David Risinger has given his Buy ...

Vertex is strategically expanding into the pain management sector, Vertex Pharmaceuticals (NASDAQ:VRTX) is a biotechnology company with a strong track record of success in developing treatments ...